Table 3.
Clinical features of the 16 advanced-stage pulmonary lymphoepithelioma-like carcinoma patients
| Patient ID | Age | Gender | Smoking status, smoking pack year | Disease stage | Treatment regimen received | Best response | Immunotherapy, best response | # of CNVs detected | TMB (mutations/Mb) | PD-L1 TPS (%) | Degree of lymphoid cell infiltration | Date of diagnosis | OS as of last follow-up date (months) | Survival status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P09 | 48 | Male | No | IIIB | CT | PR | No | 2 | 0 | 0 | 40% | 2016/6/27 | 30.0 | Alive |
| P19 | 55 | Female | No | IIIB | CT | – | No | 0 | 1.6 | 10 | 40% | 2018/11/13 | 1.0 | Alive |
| P21 | 66 | Female | No | IIIB | CT | SD | No | 0 | 0.8 | 0 | 1% | 2018/8/21 | 3.7 | Alive |
| P28a | 49 | Female | No | IIIB | CT | Nivolumab, SD | – | 60 | 5% | 2017/4/12 | 19.0 | Alive | ||
| P25 | 45 | Male | Smoker, 3 | IIIC | CT | – | No | 7 | 6.3 | 0 | 30% | 2018/5/5 | 6.7 | Alive |
| P26 | 57 | Male | Smoker, 40 | IIIC | CT + RT | SD | No | 1 | 2.4 | 10 | 30% | 2018/6/10 | 4.6 | Alive |
| P06 | 32 | Female | Non-smoker (exposure to second-hand smoke) | IVA | Neo CT + S + adj CT | PR | No | 7 | 2.4 | 10 | 8% | 2016/11/17 | 25.3 | Alive |
| P07 | 76 | Male | No | IVA | CT + RT | SD | No | 8 | 3.2 | 0 | 10% | 2017/4/6 | 20.7 | Alive |
| P13 | 49 | Male | Smoker, 20 | IVA | CT | PR | No | 1 | 0 | 30 | 30% | 2018/7/13 | 5.0 | Alive |
| P12 | 60 | Female | No | IVA | CT | PR | No | 4 | 15.9 | 30 | 10% | 2018/7/9 | 4.9 | Alive |
| P03 | 65 | Female | No | IVA | Not treated | – | No | 5 | 0.8 | 10 | 30% | 2016/11/28 | 22.7 | Alive |
| P29a | 48 | Male | No | IVA | CT | SHR-1201, SD | – | – | 15 | 5% | 2017/2/28 | 13.0 | Alive | |
| P11 | 24 | Female | No | IVB | CT | PR | No | 3 | 5.6 | 20 | 40% | 2018/3/15 | 9.0 | Alive |
| P16 | 65 | Female | No | IVB | CT | SD | No | 7 | 2.4 | 0 | 10% | 2015/8/9 | 40.7 | Alive |
| P18 | 39 | Female | No | IVB | CT | SD | No | 0 | 1.6 | 80 | 10% | 2018/10/31 | 1.9 | Alive |
| P10 | 40 | Male | Smoker, 15 | IVB | Not treated | – | No | 2 | 0 | 5 | 5% | 2018/3/29 | 7.1 | Alive |
– Data not available
Adj CT adjuvant chemotherapy,CNV copy number variation, CT chemotherapy, Neo CT neoadjuvant chemotherapy, OS overall survival, PR partial response, RT radiotherapy, S surgery, SD stable disease, TMB tumor mutation burden, TPS tumor positive score
aPatients P28 and P29 did not have adequate tissue samples for genomic profiling